Rare genetic variants potentially involved in ovarian hyperstimulation syndrome

[1]  K. Coetzee,et al.  Risk of ovarian torsion is reduced in GnRH agonist triggered freeze-all cycles: a retrospective cohort study , 2018, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[2]  E. Manara,et al.  Variant discovery in patients with Mendelian vascular anomalies by next-generation sequencing and their use in patient clinical management. , 2017, Journal of vascular surgery.

[3]  K. Alitalo,et al.  VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling , 2017, Circulation research.

[4]  S. Seneca,et al.  Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition , 2015, Journal of Assisted Reproduction and Genetics.

[5]  J. García-Velasco,et al.  Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. , 2015, Fertility and Sterility.

[6]  Gemma Escribano,et al.  Severe Ovarian Hyperstimulation Syndrome After Gonadotropin-Releasing Hormone (Gnrh) Agonist Trigger And ''Freeze-All'' Approach In Gnrh Antagonist Protocol , 2015 .

[7]  F. Gode,et al.  Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. , 2014, Reproductive biomedicine online.

[8]  P. de Mazancourt,et al.  Associations between Individual and Combined Polymorphisms of the TNF and VEGF Genes and the Embryo Implantation Rate in Patients Undergoing In Vitro Fertilization (IVF) Programs , 2014, PloS one.

[9]  J. Llácer,et al.  Pharmacogenetics of ovarian response. , 2014, Pharmacogenomics.

[10]  P. Devroey,et al.  Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. , 2014, Fertility and sterility.

[11]  S. Simmens,et al.  Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation , 2013, Reproductive Biology and Endocrinology.

[12]  P. de Mazancourt,et al.  Genetic Polymorphisms Influence the Ovarian Response to rFSH Stimulation in Patients Undergoing In Vitro Fertilization Programs with ICSI , 2012, PloS one.

[13]  S. Soares.  Etiology of OHSS and use of dopamine agonists. , 2012, Fertility and sterility.

[14]  A. Stavreus-Evers,et al.  Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? , 2011, Human reproduction update.

[15]  G. Griesinger,et al.  Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. , 2011, Fertility and sterility.

[16]  N. Chow,et al.  Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach , 2011, Oncogene.

[17]  F. Bahram,et al.  VEGF-mediated signal transduction in lymphatic endothelial cells. , 2010, Pathophysiology : the official journal of the International Society for Pathophysiology.

[18]  B. Rizk.  Genetics of ovarian hyperstimulation syndrome , 2009 .

[19]  A. Delvigne.  Epidemiology of OHSS , 2009 .

[20]  B. Rizk.  Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. , 2009, Reproductive biomedicine online.

[21]  C. Simón,et al.  Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. , 2008, Human reproduction update.

[22]  F. Morón,et al.  Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS) , 2006, Pharmacogenetics and genomics.

[23]  Jiann‐Loung Hwang,et al.  Persistent megalocystic ovary following in vitro fertilization in a postpartum patient with polycystic ovarian syndrome. , 2006, Taiwanese journal of obstetrics & gynecology.

[24]  C. Nappi,et al.  A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  C. Simón,et al.  Administration of Moderate and High Doses of Gonadotropins to Female Rats Increases Ovarian Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-2 Expression that Is Associated to Vascular Hyperpermeability1 , 2003, Biology of reproduction.

[26]  Serge Rozenberg,et al.  Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). , 2003, Human reproduction update.

[27]  M. Waner,et al.  Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma , 2002, Genes, chromosomes & cancer.

[28]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[29]  J. Smitz,et al.  The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. , 1997, Human reproduction update.

[30]  M. Breckwoldt,et al.  Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. , 1995, The Journal of clinical endocrinology and metabolism.